About Artrya
Artrya is a company based in Perth (Australia) founded in 2018 by John Konstantopoulos. Artrya offers products and services including Salix Coronary Anatomy. Artrya operates in a competitive market with competitors including Qianglian Zhichuang, PrediSurge, Saigeware Technologies, x-cardiac and Topspin Medical, among others.
- Headquarter Perth, Australia
- Founders John Konstantopoulos
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Artrya Limited
-
Annual Revenue
$18.28 K (USD)0as on Jun 30, 2025
-
Net Profit
-$10.72 M (USD)-17.19as on Jun 30, 2025
-
EBITDA
-$13.64 M (USD)-30.13as on Jun 30, 2025
-
Latest Funding Round
$9.5 M (USD), Post-IPO
Feb 14, 2025
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Artrya
Artrya is a publicly listed company on the ASX with ticker symbol AYA in Australia, operating in the Technology services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Artrya
Artrya offers a comprehensive portfolio of products and services, including Salix Coronary Anatomy.
AI for analyzing coronary artery disease through CCTA imaging.
People of Artrya
Unlock access to complete
Unlock access to complete
Funding Insights of Artrya
Investments & Acquisitions by Artrya
Investment portfolio details for Artrya
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Artrya
Detailed financials for Artrya
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Artrya Comparisons
Peer comparison for Artrya
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Artrya
Artrya operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Qianglian Zhichuang, PrediSurge, Saigeware Technologies, x-cardiac and Topspin Medical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-driven solutions for cerebrovascular disease diagnosis and treatment are developed.
|
|
| Locked | Locked | Locked |
Provider of decision making tools for cardiologists
|
|
| Locked | Locked | Locked |
AI-based decision support tool for cardiac and pulmonary practices
|
|
| Locked | Locked | Locked |
An AI-based cardiac diagnosis tool is provided for healthcare professionals.
|
|
| Locked | Locked | Locked |
Develops intravascular MRI catheters for coronary artery applications.
|
Detailed competitors of Artrya
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Artrya
Complete news archive for Artrya
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Artrya
Artrya was founded in 2018 and raised its 1st funding round 7 years after it was founded.
Artrya is headquartered in Perth, Australia. It is registered at Perth, Western Australia, Australia.
Annual revenue of Artrya is $18.28K as on Jun 30, 2025.
Artrya was founded in 2018 in Perth, Australia, within the healthcare technology sector. Software is developed to support providers in identifying coronary artery diseases through AI-driven analysis. Operations include disease detection, patient data processing, and report generation. The platform is utilized by medical professionals for enhanced cardiovascular assessments in clinical settings.
Artrya's top competitors include Saigeware Technologies, x-cardiac and PrediSurge.
Artrya offers Salix Coronary Anatomy.
Yes, Artrya is publicly traded on ASX under the ticker symbol AYA.
The ticker symbol of Artrya is AYA on ASX.